A phase I study of LBH589 [panobinostat] in combination with paclitaxel and carboplatin +/- bevacizumab the treatment of solid tumors.

Trial Profile

A phase I study of LBH589 [panobinostat] in combination with paclitaxel and carboplatin +/- bevacizumab the treatment of solid tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2013

At a glance

  • Drugs Panobinostat (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
  • Indications Breast cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jul 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
    • 07 Jul 2010 Status changed from suspended to completed as reported by ClinicalTrials.gov.
    • 10 Jun 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top